Enhancement of Endothelial Progenitor Cell Numbers and Migration by H1152, a Rho Kinase Specific Inhibitor

Eunju O; Seung Woo LEE; Hyun-Sun LEE; Hee-Suk LIM; Hyun-Young AHN; Jong-Chul SHIN; Yonggoo KIM; Young Ae JOE

doi:10.1271/bbb.110468

Biochemistry & Molecular Biology Notes

Enhancement of Endothelial Progenitor Cell Numbers and Migration by H1152, a Rho Kinase Specific Inhibitor

Eunju O, Seung Woo LEE, Hyun-Sun LEE, Hee-Suk LIM, Hyun-Young AHN, Jong-Chul SHIN, Yonggoo KIM, Young Ae JOE

Author information

Keywords: Rho kinase inhibitor, endothelial progenitor cell, H1152, expansion, migration

JOURNAL FREE ACCESS

2012 Volume 76 Issue 1 Pages 172-175

DOI https://doi.org/10.1271/bbb.110468

View "Advance Publication" version (January 7, 2012).

Details

Abstract

Endothelial progenitor cells (EPCs) are applied in the treatment of ischemic diseases. In ex vivo culture of human cord-blood derived EPCs, H1152, (S)-(+)-2-methyl-1-[(4-methyl-5-iso-quinolinyl) sulfonyl]-homopiperazine, markedly increased the number of EPCs. It also induced EPC migration, stimulated the phosphorylation of AKT, and reduced the expression of p27 in the EPCs. Thus H1152 can be used effectively in ex vivo expansion of EPCs.

Corresponding author

Register with J-STAGE for free!